H
Hongxing Pan
Researcher at Centers for Disease Control and Prevention
Publications - 38
Citations - 1987
Hongxing Pan is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Medicine & Immunogenicity. The author has an hindex of 8, co-authored 17 publications receiving 1021 citations.
Papers
More filters
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Yaling Hu,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Yuansheng Hu,Xiao-Yong Liu,Cong-Bing Jiang,Jingxin Li,Minnan Yang,Yan Song,Xiangxi Wang,Qiang Gao,Fengcai Zhu +19 more
TL;DR: The primary safety endpoint was adverse reactions within 28 days after injection in all participants who were given at least one dose of study drug (safety population).
Journal ArticleDOI
A Novel Influenza A (H1N1) Vaccine in Various Age Groups
Fengcai Zhu,Hua Wang,Han-hua Fang,Jian Guo Yang,Xiao Jun Lin,Xiaofeng Liang,Xuefeng Zhang,Hongxing Pan,Fan-Yue Meng,Yue Mei Hu,Wen-Dong Liu,Chang-Gui Li,Wei Li,Xiang Zhang,Jin Mei Hu,Wei Bing Peng,Bao Ping Yang,Pei Xi,Hua-Qing Wang,Jingshan Zheng +19 more
TL;DR: These data suggest that a single dose of 15 microg of hemagglutinin antigen without alum adjuvant induces a typically protective immune response in the majority of subjects between 12 and 60 years of age.
Journal ArticleDOI
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
Jingxin Li,Lihua Hou,Xiling Guo,Pengfei Jin,Shipo Wu,Jiahong Zhu,Hongxing Pan,Xue Wang,Zexing Song,Jingxuan Wan,Lunbiao Cui,Junqiang Li,Yin Chen,Xue-Wen Wang,L. Jin,Jingxian Liu,Fengjuan Shi,Xiaoyu Xu,Tao Zhu,Wei Chen,Fengcai Zhu +20 more
TL;DR: In this paper , the authors evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous boost in adults previously vaccinated with CoronaVAC in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial.
Journal ArticleDOI
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.
TL;DR: Current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlate of protection and issues related to CO VID-19 correlated of protection are reviewed.
Posted ContentDOI
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Biao Kan,Yaling Hu,Haiyan Mao,Qian-Qian Xin,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Xuejie Gong,Chuan Qin,Yuansheng Hu,Xiao-Yong Liu,Guo-Liang Cui,Cong-Bing Jiang,Hengming Zhang,Jingxin Li,Minnan Yang,Xiao-Juan Lian,Yan Song,Jinxing Lu,Xiangxi Wang,Miao Xu,Qiang Gao,Fengcai Zhu +29 more
TL;DR: Favorable safety and immunogenicity of CoronaVac was demonstrated on both schedules and both dosages, which support the conduction of phase 3 trial with optimum schedule/dosage per different scenarios.